

Please type a plus sign (+) inside this box →

PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Notation of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

1

Q


1

Complete if Known

Application Number	10/602,927
Filing Date	06-24-2003
First Named Inventor	MERRILL, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	USA2001/0172 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
XZ		CHABAS, Dorothee et al., The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease, Science, (2001), Vol. 294, pp. 1731 - 1735	
XZ		STEINMAN, Lawrence et al., Multiple Sclerosis: Deeper Understanding of Its Pathogenesis Reveals New Targets for Therapy, Annu. Rev. Neurosci, (2002), Vol. 25, pp. 491 - 505	

Examiner Signature		Date Considered	03/16/2006
--------------------	---	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. **2** Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/602,927
Filing Date	06-24-2003
First Named Inventor	MERRILL, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	USA2001/0172 - US - NP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	3/17/06
-----------------------	---	--------------------	---------

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee


?

1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/602,927
		Filing Date	06-24-2003
		First Named Inventor	MERRILL, et al.
		Group Art Unit	Not Yet Known
		Examiner Name	Not Yet Known
Sheet	2	of	2
		Attorney Docket Number	
		USA2001/0172 - US - NP	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
XZ		J. SODEK et al., Regulation of Osteopontin Regulation in Osteoblasts, Ann. NY Acad. Sci., Vol. 270, April 21, 1995, pp. 223-241	
XZ		K. IRIE et al., Morphological and Immunocytochemical Characterization of Primary Osteogenic Cell Cultures Derived From Fetal Rat Cranial Tissue, The Anatomical Record, Vol. 252, No. 4, Dec. 1998, pp. 554-567	
XZ		N. TANI-ISHII et al., Osteopontin antisense deoxyoligonucleotides inhibit bone resorption by mouse osteoclasts in vitro, J. Periodontal Res., Vol. 32, No. 6, August 1997, pp. 480-486	
XZ		R. SELVARAJU et al., Osteopontin is upregulated during in vivo demyelination and remyelination and enhances myelin formation in vitro, Mol. Cell. Neurosci., Vol. 25, No. 4, April 2004, pp. 707-721	
XZ		S. JANDER et al., Osteopontin: A Novel Axon-Regulated Schwann Cell Gene, J. Neurosci. Res. Vol. 67, No. 2, Jan. 15, 2002, pp. 156-166	

Examiner Signature		Date Considered	03/16/2006
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.